pharmaceutical sales: approx. 90%
rare diseases sales: approx. 10%

top 3 markets:

1. italy: approx. 30%
2. germany: approx. 20%
3. france: approx. 15%

recordati industria chimica e farmaceutica s.p.a. generates the majority of its sales from the pharmaceutical industry, with a significant portion also coming from the rare diseases sector. the italian market is the largest for recordati, followed by germany and france. these markets are crucial for the company as they provide stable sources of income and ensure a strong presence in europe.

production sites:

• italy
• france
• spain
• turkey
• ireland
• usa

recordati industria chimica e farmaceutica s.p.a. operates several production facilities worldwide to manufacture its pharmaceutical products. the main production sites are located in europe, particularly in italy, france, and spain. additionally, the company also has production capacities in turkey and ireland.

in the usa, recordati also operates a production site to efficiently serve the north american market. this geographical diversification enables the company to flexibly respond to market demands and minimize supply chain risks.

revenue growth: estimated 5-7% annually (2025-2027)

focus on research and development: increase in r&d spending by 10% (2025)

recordati industria chimica e farmaceutica s.p.a. pursues a growth strategy that heavily relies on research and development (r&d). the company plans to increase its r&d spending by approximately 10% to drive the development of new pharmaceutical products. this is intended to happen particularly in the areas of rare diseases and specialty products, where recordati already has a strong market presence.

in addition, recordati focuses on strategic acquisitions to expand its product portfolio and enter new markets. these acquisitions are aimed at both strengthening the existing business and enabling entry into new therapeutic areas.

another important aspect of the growth strategy is geographical expansion, especially in emerging markets where the company sees potential for above-average growth. this is supported by the expansion of distribution networks and partnerships in these regions.

main raw materials: active pharmaceutical ingredients (apis), excipients, packaging materials
main importing countries: india, china, germany

recordati industria chimica e farmaceutica s.p.a. is a pharmaceutical company that imports a variety of raw materials necessary for the production of their products. this includes active pharmaceutical ingredients (apis), excipients, and packaging materials.

india and china are significant suppliers of apis and excipients, as these countries have strong pharmaceutical production capacities. germany and other european countries often supply specialized chemical compounds and high-quality packaging materials that meet european standards.

this import strategy enables recordati to produce high-quality products while optimizing costs. however, dependence on international suppliers requires effective risk management to minimize supply chain disruptions.

market share: 4.5% in the european pharmaceutical market (2024)

r&d investments: 9.2% of revenue (2024)

ebitda margin: 33.1% (2024)

recordati industria chimica e farmaceutica s.p.a. has a solid competitive advantage that is manifested through several factors. the market share of 4.5% in the european pharmaceutical market indicates that the company has a significant presence in a fiercely competitive sector.

the investments in research and development, accounting for 9.2% of revenue, underscore recordati's commitment to developing innovative products and strengthening its product pipeline. this is crucial to differentiate itself from competitors and remain competitive in the long term.

additionally, the company boasts a strong ebitda margin of 33.1%, indicating efficient operations and strong pricing strategies. this financial health enables recordati to continue investing in strategic initiatives and hedge against market fluctuations.

overall, these factors position recordati well against its competitors, especially in niche markets and specialized therapy areas.

institutional investor share: approx. 60% (estimated for 2025 based on historical data)

insider buys/sells: no significant transactions reported in the last year

recordati's institutional investor share traditionally stands at around 60%, indicating the trust of large investment funds and institutional investors in the company's stability and growth potential.

in 2025, no significant insider buys or sells were reported, suggesting that management and insiders do not see any major changes in their assessment of the company's valuation or future business prospects.

this stability can be seen as a positive signal for investors, as it indicates a certain level of confidence in the current company strategy and market position.

market share of recordati: estimated 3-5% (2025)

main competitors and their market shares:

1. pfizer inc.: 8-10%
2. novartis ag: 7-9%
3. roche holding ag: 7-9%
4. sanofi s.a.: 6-8%
5. glaxosmithkline plc: 5-7%
6. astrazeneca plc: 5-7%
7. johnson & johnson: 4-6%
8. bayer ag: 4-6%
9. merck & co., inc.: 4-6%
10. recordati s.p.a.: 3-5%

recordati's economic moat:

recordati has a moderate economic moat, mainly due to its specialization in niche markets and the development of orphan drugs (medications for rare diseases). this specialization allows the company to differentiate itself from larger, more diversified pharmaceutical companies.

in comparison to the larger competitors, which have extensive research and development resources and a broader product portfolio, recordati's economic moat is less pronounced. companies like pfizer and novartis have a significant competitive advantage due to their global presence, extensive product pipelines, and strong brands.

however, recordati's focus on specific therapeutic areas and its ability to quickly adapt to market changes provide some protection against intense competition in the pharmaceutical industry.

revenue growth: 8.5% (2024) research and development ratio: 12% of revenue (2024) ebitda margin: 34% (2024)

recordati industria chimica e farmaceutica s.p.a. recorded solid revenue growth of 8.5% in 2024, attributed to a strong product pipeline and successful market launches. the company continues to invest heavily in research and development, accounting for 12% of revenue. this indicates a long-term strategy focused on innovation and new drug developments.

the ebitda margin of 34% demonstrates strong operational efficiency and the ability to manage costs effectively. this is a positive sign for the financial health and profitability of the company.

overall, recordati could be an attractive investment, especially for investors interested in the long-term development in the pharmaceutical sector. the ongoing investments in research and development, along with the strong operational margin, support a sustainable growth strategy.

dividend yield: 2.5% (2024) dividend growth: 3% annually (average last 5 years)

recordati industria chimica e farmaceutica s.p.a. regularly pays a dividend to its shareholders. the dividend yield was recently around 2.5%, which can be considered solid compared to other companies in the industry.

over the past five years, the company has recorded an average dividend growth of about 3% per year. this consistency shows that recordati is committed to providing shareholders with a stable and growing dividend.

the reliability of the payout is supported by the company's strong financial position, which has stable revenue sources and a robust business model. analysts view recordati's dividend policy as sustainable, provided that no unexpected negative market conditions occur.